Study On Inhibiting Effect Of MG-132 On Hepatocellular Cancer Cells BEL-7402

Background : Hepatocarcinoma is a common , difficult-to-treat cancer. Hepatocarcinoma is associated with a dismal prognosis in most patients, with a median survival after after diagnosis of less than 6 months. Chemotherapy is still the main means for treating hepotocellular carcinoma.The ineffectiveness of chemotherapy in HCC patients may be due to the resistance of HCC cells to the apoptosis induced by cytotoxity agents. Side effects from cytotoxic therapy also limits its usefulness.Newer agents are needed to selectively kill the cancer cells.Ubiquitin-proteasome pathway is the major proteolytic mechanism which plays a critical role in the degradation of proteins involved in cell cycle control and tumor growth,such as p53, p21, Bax, I-κB.Inhibiting the degradation of such proteins should have profound effects on tumor cells proliferation and cause cells to undergo apoptosis.MG-132, a proteasomal inhibitor, has been found to induce apoptosis in many kinds of tumor cells but not in normal cells.Objective: The present study was designed to investigate the effect and the mechanism of MG-132 (Z-Leu-Leu-Leu-CHO) on proliferation and apoptosis of human heptocellular cell line BEL-7402; to determine whether MG-132 can raise the anti-BEL7402 cells effect of epirubicin and its molecular mechanism . and to settle experimental basis for the clinical application of MG-132.